Financial Report: Abbvie
1Q Revenues: $13.5 billion (+4%)
1Q Earnings: $4.5 billion (+26%)
Comments: Immunology portfolio sales were $6.1 billion, up 7% in the quarter. Humira revenues were $4.7 billion, down 2.7%. U.S. Humira revenues were $3.99 billion, an increase of 2.2 percent. Internationally, Humira revenues were $743 million, a down of 22.6%, due to biosimilar competition. Global Skyrizi sales were $940 million, an increase of 63.7%. Global Rinvoq revenues were $465 million, an increase of 53.6%. Hematologic oncology portfolio sales were $1.6 billion, a decrease of 1.6%. Global Imbruvica sales were $1.17 billion, a decrease of 7.4%, with U.S. sales of $874 million and international profit sharing of $299 million. Global Venclexta revenues were $473 million, an increase of 16.9%. Global revenues from the neuroscience portfolio were $1.48 billion, an increase of 19.2%. Global Botox Therapeutic revenues were $614 million, an increase of 15.4%. Vraylar sales were $427 million, up 23.4%. Global Ubrelvy revenues were $138 million.